FindMyKOL

Aasim Sehbai, MD

Basic profile

University of Alabama at Birmingham

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionAnniston, AL · SoutheastSpecialtyHematology / OncologyFocusOncology
Active KOLEmergingFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Aasim Sehbai is an Oncology physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 34 publications with 206 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
34publications

Publications indexed by OpenAlex. Counts exclude supporting files.

206citations

Citations across these publications.

8h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
77companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

77 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Novartis Pharmaceuticals Corporation
    Program year202537 payments
    $1,701
  • Janssen Biotech, Inc.
    Program year202517 payments
    $397
  • AstraZeneca Pharmaceuticals LP
    Program year202513 payments
    $335
All 189 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    45.4%
    Other antiemetics32.2%
    Fosaprepitant100%
    Part B, office-administered≥20 patients
    Serotonin-3 Receptor Antagonist12.7%
    Ondansetron hydrochloride72%Palonosetron hcl23%Palonosetron Hcl4%Ondansetron Hcl1%Ondansetron Odt1%
    Part D + Part B≥39 patients

    + 5 more classes in this area

  • Cancer & immunology

    21%
    Microtubule Inhibitor17.2%
    Paclitaxel99%Abraxane0%Docetaxel0%
    Part D + Part B<11 patients
    Platinum-based Drug1.1%
    Carboplatin87%Oxaliplatin14%
    Part D + Part B≥15 patients

    + 17 more classes in this area

  • Musculoskeletal

    18%
    RANK Ligand Inhibitor18%
    Denosumab98%Xgeva1%Prolia1%
    Part D + Part B≥35 patients
    Xanthine oxidase inhibitor0%
    Allopurinol100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)0.1% facility · 99.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”